Lima Thayane Furtado Rolim, Cordeiro Lia Poti Gomes, Gomes Kirla Wagner Poti, Rodrigues Carlos Ewerton Maia
Resident in Rheumatology, General Hospital of Fortaleza (HGF), Fortaleza, Brazil.
Resident in Internal Medicine, Waldemar Alcântara General Hospital (HGWA), Fortaleza, Brazil.
Adv Rheumatol. 2025 Jul 17;65(1):32. doi: 10.1186/s42358-025-00465-4.
Biosimilars reduce the cost of biologic therapy without compromising safety and effectiveness. In this study we evaluated Brazilian rheumatologists' knowledge and perceptions of biosimilars.
Cross-sectional and descriptive study based on a questionnaire containing 17 items on familiarity, knowledge and perceptions of biosimilars.
Answers were received from 135 rheumatologists, of whom 97.8% were familiar with biosimilars and 92.5% had at some time prescribed them, but only 47.7% felt comfortable prescribing them to stable patients and 62.2% strongly disagreed with automatic substitution. In addition, 51.9% preferred naive patients when starting treatment with biosimilars.
Despite the growing acceptance of biosimilars, many physicians remain reluctant. Evidence-based continuing education is essential to clarify these issues.
生物类似药在不影响安全性和有效性的前提下降低了生物治疗的成本。在本研究中，我们评估了巴西风湿病学家对生物类似药的了解和看法。
基于一份包含17项关于生物类似药的熟悉程度、知识和看法的问卷进行横断面描述性研究。
共收到135名风湿病学家的回复，其中97.8%熟悉生物类似药，92.5%曾在某些时候开具过此类药物，但只有47.7%的人对给稳定患者开具生物类似药感到放心，62.2%的人强烈反对自动替换。此外，51.9%的人在开始使用生物类似药治疗时更倾向于初治患者。
尽管生物类似药的接受度不断提高，但许多医生仍然持谨慎态度。基于证据的继续教育对于阐明这些问题至关重要。
